IgE-mediated allergic asthma
|
disease |
Immune System Diseases
|
Disease or Syndrome
|
133
|
46
|
0.010 |
None |
< 0.001 |
1 |
|
2011 |
2011 |
Caffeine related disorders
|
group |
|
Mental or Behavioral Dysfunction
|
360
|
56
|
0.010 |
None |
< 0.001 |
1 |
|
2019 |
2019 |
Differentiated Thyroid Gland Carcinoma
|
disease |
|
Neoplastic Process
|
242
|
72
|
0.010 |
None |
< 0.001 |
1 |
|
2019 |
2019 |
Hyperplastic Polyp
|
disease |
Pathological Conditions, Signs and Symptoms
|
Neoplastic Process
|
204
|
22
|
0.010 |
None |
< 0.001 |
1 |
|
2013 |
2013 |
Monoclonal Gammopathy of Undetermined Significance
|
disease |
Immune System Diseases; Hemic and Lymphatic Diseases
|
Neoplastic Process
|
221
|
12
|
0.010 |
None |
< 0.001 |
1 |
|
2005 |
2005 |
Teratozoospermia
|
disease |
Male Urogenital Diseases
|
Disease or Syndrome
|
47
|
|
0.010 |
None |
< 0.001 |
1 |
|
2015 |
2015 |
Congenital neurologic anomalies
|
group |
Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases
|
Congenital Abnormality
|
43
|
1
|
0.010 |
None |
< 0.001 |
1 |
|
2009 |
2009 |
Fatigue
|
phenotype |
Pathological Conditions, Signs and Symptoms
|
Sign or Symptom
|
445
|
48
|
0.110 |
None |
< 0.001 |
1 |
|
2018 |
2018 |
Tumour budding
|
disease |
|
Neoplastic Process
|
71
|
8
|
0.010 |
None |
< 0.001 |
1 |
|
2017 |
2017 |
Skin carcinoma
|
disease |
Neoplasms; Skin and Connective Tissue Diseases
|
Neoplastic Process
|
134
|
20
|
0.010 |
None |
< 0.001 |
1 |
|
2020 |
2020 |
Allergic asthma
|
disease |
Respiratory Tract Diseases; Immune System Diseases
|
Disease or Syndrome
|
371
|
55
|
0.010 |
None |
< 0.001 |
1 |
|
2011 |
2011 |
Monoclonal Gammapathies
|
group |
Immune System Diseases; Hemic and Lymphatic Diseases
|
Neoplastic Process
|
62
|
2
|
0.010 |
None |
< 0.001 |
1 |
|
2005 |
2005 |
Carcinoma, Lewis Lung
|
disease |
Neoplasms
|
Neoplastic Process; Experimental Model of Disease
|
186
|
|
0.020 |
None |
0.500 |
2 |
|
2017 |
2019 |
Progressive Neoplastic Disease
|
phenotype |
|
Neoplastic Process
|
384
|
40
|
0.020 |
None |
0.500 |
2 |
|
2009 |
2014 |
Progressive cGVHD
|
disease |
|
Disease or Syndrome
|
384
|
40
|
0.020 |
None |
0.500 |
2 |
|
2009 |
2014 |
Skin lesion
|
group |
Skin and Connective Tissue Diseases
|
Disease or Syndrome
|
563
|
51
|
0.060 |
None |
0.667 |
6 |
|
2014 |
2019 |
Epilepsy
|
disease |
Nervous System Diseases
|
Disease or Syndrome
|
1124
|
250
|
0.030 |
None |
0.667 |
3 |
|
2018 |
2019 |
Skin Carcinogenesis
|
disease |
Pathological Conditions, Signs and Symptoms; Neoplasms
|
Neoplastic Process
|
194
|
7
|
0.030 |
None |
0.667 |
3 |
|
2010 |
2017 |
Metabolic Syndrome X
|
disease |
Nutritional and Metabolic Diseases
|
Disease or Syndrome
|
1083
|
477
|
0.040 |
None |
0.750 |
4 |
|
2009 |
2018 |
Non-alcoholic Fatty Liver Disease
|
disease |
Digestive System Diseases
|
Disease or Syndrome
|
1016
|
189
|
0.050 |
None |
0.800 |
5 |
2
|
2008 |
2019 |
Fatty Liver
|
disease |
Digestive System Diseases
|
Disease or Syndrome
|
757
|
35
|
0.050 |
None |
0.800 |
5 |
|
2013 |
2019 |
Mycosis Fungoides
|
group |
Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases
|
Neoplastic Process
|
243
|
8
|
0.050 |
None |
0.800 |
4 |
|
2004 |
2020 |
Obesity
|
disease |
Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases
|
Disease or Syndrome
|
2459
|
900
|
0.300 |
None |
0.833 |
17 |
1
|
2007 |
2019 |
Keloid
|
disease |
Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases
|
Acquired Abnormality
|
129
|
14
|
0.060 |
None |
0.833 |
6 |
|
2006 |
2019 |
Experimental Organism Basal Cell Carcinoma
|
phenotype |
Neoplasms
|
Neoplastic Process
|
437
|
63
|
0.060 |
None |
0.833 |
6 |
2
|
2002 |
2020 |